Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 1, Number 4—October 1995

An Outbreak of Hemoytic Uremic Syndrome Associated with Antibiotic Treatment of Hospital Inpatients for Dysentery

Sami Al-Qarawi*, Robert E. Fontaine†, and Mohammed-Saeed Al-Qahtani*
Author affiliations: *Saudi Arabian Field Epidemiology Training Program, Ministry of Health, Saudi Arabia; †Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Main Article

Table 2

Risk of developing hemolytic uremic syndrome (HUS) by antibiotic combinations used for in-hospital treatment of dysentery during a community outbreak of antibiotic-resistant Shigella dysenteriae type 1, Najran, Saudi Arabia, March through May 1993

Dysentery patients
Antibiotic combination Developed HUS(10) Total (42) HUS rate/100 Risk ratio a confidence interval b
Ineffective c antibiotics without nalidixic acid d-j 6 12 50 4.3 1.3-15
Ampicillin combinations without nalidixic acid d-f 5 7 71 6.2 1.9-20
Ineffective antibiotics without nalidixic acid or ampicillin g-j 1 5 20 1.7 0.22-14
Ampicillin and nalidixic acid with (2) or without metronidazole (3) 1 3 33 2.9 0.40-20
Trimethoprim-sulfamethoxazole, nalidixic acid and metronidazole 0 1 0 0
Nalidixic acid with (24) or without (2) metronidazole (reference) 3 26 12 1.0 Reference

a Relative to the reference antibiotic combination (nalidixic acid with or without metronidazole).
b Taylor series approximation standard.
c Antibiotics to which the outbreak strain of S. dysenteriae type 1 was resistant (ampicillin, trimethoprim-sulfamethoxazole) or which are ineffective against shigella (metronidazole, gentamicin, or erythromycin).
d Ampicillin and metronidazole (4 patients). e Ampicillin, metronidazole, and gentamicin (2 patients).
f Ampicillin only (1 patient). g Trimethoprim-sulfamethoxazole and metronidazole (1 patient).
h Trimethoprim-sulfamethoxazole, erythromycin, and metronidazole (1 patient). i Metronidazole only (2 patients).
j Erythromycin and metronidazole (1 patient).

Main Article

Page created: December 20, 2010
Page updated: December 20, 2010
Page reviewed: December 20, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.